Medicare GLP-1 Bridge Program*

Resource Guide to Access Wegovy® for Obesity

ELIGIBLE MEDICARE PATIENTS PAY ONLY **$50 PER MONTH**[1,†]

When[1]: Available as of July 1, 2026

Eligible Medicare patients can access all doses of Wegovy® pen & pill for only $50 per month.

- No separate prescription needed for needles as they are integrated into the Wegovy® pen device
- Medicare GLP-1 Bridge patients do **not** need a new prior authorization if switching between Wegovy® pen and pill

Indication and Usage

Wegovy® injection and tablets are indicated in combination with a reduced calorie diet and increased physical activity to:

- Reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardialinfarction, or non-fatal stroke) in adults with established CV disease and either obesity oroverweight
- Reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight in the presence of at least one weight-related comorbidity

Limitations of Use: Concomitant use of Wegovy® tablets or Wegovy® injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended

*The Medicare GLP-1 Bridge Program is a nationwide, short-term CMS program designed to cover select weight management drugs for Medicare Part D beneficiaries.[1]

†Terms apply. For eligible Medicare patients prescribed Wegovy® for a covered FDA-approved indication. Eligibility criteria will be determined by CMS. This information is not a guarantee of coverage. Month defined as 1 box of 4 pens of Wegovy® and 1 bottle of 30 tablets of Wegovy®. Visit https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge to learn more.[1,2]

CMS, Centers for Medicare & Medicaid Services; FDA, US Food and Drug Administration; GLP-1, glucagon-like peptide-1.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

- **In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined**
- **Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy® and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy®**

Important Safety Information

Contraindications

- Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy®. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with Wegovy®

Scan here to learn more about the Medicare GLP-1 Bridge Program for Wegovy®

novo nordisk®

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

wegovy® semaglutide tablets 25mg injection 1.7mg | 2.4mg | 7.2mg

PRESCRIBERS

Medicare GLP-1 Bridge Program Eligibility

Patients are eligible if all of the following apply:

- 18 years of age or older
- Enrolled in a **Medicare Part D** plan (stand alone PDP or MA PD), including Special Needs Plans (SNPs), employer/union group waiver plans (EGWPs), Limited Income Newly Eligible Transition (LI NET), and dual-eligible beneficiaries who are enrolled in eligible Part D plan types
- Medication is prescribed **for weight management, in combination with current and ongoing lifestyle modification** consistent with the applicable FDA-approved label
- **BMI ≥35** OR **BMI ≥30** + 1 or more of the following comorbidities OR **BMI ≥27** + 1 or more comorbidities
  - Uncontrolled HTN,* HFpEF, CKD Stage 3a or above
  - Pre-diabetes, previous stroke/MI, symptomatic PAD

*Uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications)

Patients are not eligible if:

- They are currently receiving a GLP-1 through their Part D plan or they will be receiving a GLP-1 for a Part D covered FDA-approved indication

Important Safety Information

Warnings and Precautions

- **Risk of Thyroid C-Cell Tumors:** Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
- **Acute Pancreatitis:** Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including Wegovy®. Observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea, or vomiting. If pancreatitis is suspected, discontinue Wegovy® and initiate appropriate management
- **Acute Gallbladder Disease:** Treatment with Wegovy® is associated with an increased occurrence of cholelithiasis and cholecystitis. In clinical trials in adult patients, cholelithiasis was reported by 1.6% of Wegovy® injection-treated patients and 0.7% of placebo treated patients, and by 2.5% of Wegovy® tablet-treated patients and 1% of placebo treated patients. Cholecystitis was reported by 0.6% of Wegovy® injection-treated adult patients and 0.2% of placebo treated patients. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in Wegovy® patients than in placebo patients, even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
- **Hypoglycemia:** Wegovy® lowers blood glucose and can cause hypoglycemia. In a trial of Wegovy® injection in adult patients with type 2 diabetes (T2D) and a BMI ≥27 kg/m^2, hypoglycemia was reported in more patients treated with Wegovy® versus placebo. In glycemic control clinical trials, the risk of hypoglycemia was increased when semaglutide injection or tablet was used concomitantly with insulin or an insulin secretagogue (e.g., sulfonylurea). Patients with diabetes taking Wegovy® with an insulin or insulin secretagogue may have an increased risk of hypoglycemia, including severe hypoglycemia. The use of Wegovy® in patients with type 1 diabetes or in combination with insulin has not been evaluated. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with diabetes
- **Acute Kidney Injury Due to Volume Depletion:** There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Wegovy® that could lead to volume depletion, especially during initiation and escalation of Wegovy®
- **Severe Gastrointestinal (GI) Adverse Reactions:** Use of Wegovy® has been associated with GI adverse reactions, sometimes severe. In adult clinical trials, severe GI adverse reactions were reported more frequently among patients receiving Wegovy® than placebo. Severe GI adverse reactions were reported in 4.1% and 0.9% of Wegovy®-injection treated and placebo treated patients, respectively, and in 2% of Wegovy® tablet-treated and 0% of placebo treated patients, respectively. Severe GI adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. Wegovy® is not recommended in patients with severe gastroparesis
- **Hypersensitivity Reactions:** Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with Wegovy®. If hypersensitivity reactions occur, discontinue use of Wegovy®, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist

BMI=body mass index; CKD, chronic kidney disease; HFpEF, heart failure with preserved ejection fraction; HTN, hypertension; prior authorization; MI, myocardial infarction; PAD, peripheral arterial disease.

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

wegovy®
semaglutide tablets 25mg injection 1.7mg | 2.4mg | 7.2mg

PRESCRIBERS



STEP 1: SEND THE PRESCRIPTION TO THE PHARMACY

Include **"SEND TO MEDICARE GLP-1 BRIDGE FOR WEIGHT MANAGEMENT"** in the note field if electronic, or as an annotation if non-electronic, so that the **prescription is sent directly to the Medicare GLP-1 Bridge** and not the patient's Part D plan.

- **Additional information that should be included** with the script is:
  - An **obesity diagnosis code** (the E66 family).
  - The patient's **Medicare Number (MBI)**, which can be found on their red, white, and blue Medicare card.
- Since there's no option to complete the PA before getting the PA request, **you must wait to get the request from the pharmacy electronically or by fax** for your patients to be covered under Medicare GLP-1 Bridge.
- Once the pharmacy directs a claim to Medicare GLP-1 Bridge, Medicare GLP-1 Bridge will assess the patient's eligibility.
  - If the patient/product are **eligible**, the claim will still be rejected, but the Central Processor will instruct the pharmacy that a **PA is necessary**.
  - If the claim is **denied** at this step, the pharmacy will get instructions on how to **resubmit the claim**.

STEP 2: COMPLETE THE PA REQUEST

- The pharmacy needs to receive a denied claim from the Medicare GLP-1 Bridge before they can send an **Electronic Prior Authorization (ePA) request or fax form** to you for completion, typically within 24–72 hours.
  - If you haven't received the ePA or fax form from the pharmacy, visit cms.gov/glp-1-bridge.pdf to get the fax form.
- PA **approval** or **denial** will be **mailed to your patient** and **faxed to you** within 72 hours of submission, but most prior authorizations will be processed instantaneously.
  - If you believe a denial was made in error, you may resubmit the PA for re-review

BIN, bank identification number; MBI, Medicare Beneficiary Identifier; PA, prior authorization; PCN, processor control number.

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

wegovy® semaglutide tablets 25mg injection 1.7mg | 2.4mg | 7.2mg

PHARMACIES

STEP 1: DETERMINE WHETHER TO SEND THE PRESCRIPTION TO MEDICARE GLP-1 BRIDGE

Is the patient enrolled in an eligible Medicare Part D Plan?

- Patients enrolled in a **Medicare Part D** plan (stand alone PDP or MA PD), including Special Needs Plans (SNPs), employer/union group waiver plans (EGWPs), Limited Income Newly Eligible Transition (LI NET), and dual-eligible beneficiaries can access this program.

Is Wegovy® a covered drug for Medicare GLP-1 Bridge?

Yes, all doses of Wegovy® pen & pill are covered.

- Check the NDC.

Has the patient already received a GLP-1 through their Part D plan?

- If yes, route the prescription to the Part D plan—not Medicare GLP-1 Bridge.

Has the patient or prescriber said this prescription should go to Medicare GLP-1 Bridge?

- If the prescription says, "**SEND TO MEDICARE GLP-1 BRIDGE FOR WEIGHT MANAGEMENT,"** route to Medicare GLP-1 Bridge.
- This may appear in the Note field or as an annotation.
- You will need the patient's Medicare Number (MBI) to submit the claim. This can be found on their Medicare card (the red, white, and blue card). You may also ask the beneficiary for the last 4 digits of their Social Security number and use that to look up the MBI.

STEP 2: SUBMIT THE CLAIM THROUGH MEDICARE GLP-1 BRIDGE

- **Use BIN/PCN 028918 / MEDDGLP1BR to submit the claim.**
- If the patient/product are **eligible**, the claim will still be denied (Code 75 Rejection), but the Central Processor will instruct the pharmacy that a PA is needed
- If the patient is **not eligible**, you'll get a denial code with the reason.

BIN/PCN 028918 / MEDDGLP1BR

Important Safety Information

Warnings and Precautions (cont'd)

- **Diabetic Retinopathy Complications in Patients with T2D:** In a trial of adult patients with T2D and BMI ≥27 kg/m^2, diabetic retinopathy was reported by 4% of Wegovy® injection-treated patients and 2.7% of placebo patients. In a glycemic control trial evaluating a dose comparable to the 9 mg dose and the 25 mg semaglutide tablet doses in patients with T2D, 1.3% and 1.9% of patients in the 9 mg and 25 mg semaglutide group, respectively, reported moderate-severe non-proliferative diabetic retinopathy events, and 0% and 0.4% reported proliferative retinopathy events, respectively. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
- **Heart Rate Increase:** Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy® injection-treated adult patients compared to placebo in clinical trials. More adults treated with Wegovy® injection compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% vs 34%) and 20 bpm or more (26% vs 16%). Findings were similar in a trial with the Wegovy® tablets. Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy®
- **Pulmonary Aspiration During General Anesthesia or Deep Sedation:** Wegovy® delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Wegovy®
- **Never Share Wegovy® FlexTouch® Between Patients:** Wegovy® FlexTouch® must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

wegovy®
semaglutide tablets 25mg injection 1.7mg | 2.4mg | 7.2mg

STEP 3: HCP COMPLETES THE PRIOR AUTHORIZATION (PA) REQUEST

Use your usual process to send the prior authorization request to the prescriber.

- If you use an electronic system, such as CoverMyMeds, it may send the PA request automatically or require manual send.
- If you don't use an electronic system, send the request by fax to the prescriber.
- You can also notify the prescriber by phone or email.
- The prescriber can return the prior authorization by fax or ePA.

- The prescriber and patient will be notified if the prior authorization is approved or denied.
- A denial will include the reason.
- This usually happens within 72 hours and may happen sooner.

Use your usual process to check prior authorization status.

- If you use an ePA system, such as CoverMyMeds, you may get an approval or denial notification.
- If you don't use an ePA system, you may need to resubmit the claim to check if it was approved.
- If the PA has been approved, the claim will then process.

Important Safety Information

Adverse Reactions

- Most common adverse reactions (incidence ≥5%) are: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with T2D, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss

Drug Interactions

- When initiating Wegovy®, consider reducing the dose of concomitantly administered insulin secretagogues or insulin to reduce the risk of hypoglycemia. The addition of Wegovy® in patients treated with insulin has not been evaluated
- Wegovy® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy®. Consider increased clinical or laboratory monitoring for medications that have a narrow therapeutic index or that require clinical monitoring

Use in Specific Populations

- **Pregnancy:** May cause fetal harm. When pregnancy is recognized, advise the pregnant patient of the risk to a fetus. Discontinue Wegovy® in pregnant patients who are using Wegovy® for weight reduction or at least 2 months before a planned pregnancy
- **Lactation:** A clinical lactation study reported semaglutide concentrations below the lower limit of quantification in human breast milk. However, salcaprozate sodium (SNAC) and/or its metabolites are present in human milk. Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of SNAC, an absorption enhancer for Wegovy® tablets, and because there are alternative formulations of semaglutide that do not contain SNAC that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with Wegovy® tablets
- **Pediatric:** The safety and effectiveness of Wegovy® injection have not been established in pediatric patients to reduce the risk of major adverse CV events or to reduce excess body weight and maintain weight reduction long term with the 7.2 mg once weekly dosage or in those <12 years.

  The safety and effectiveness of Wegovy® tablets have not been established in pediatric patients
- **Geriatric:** In the CV outcomes trial, patients ≥75 years reported more hip and pelvis fractures on Wegovy® injection than placebo. Patients ≥75 years (Wegovy® injection and placebo) reported more serious adverse reactions overall compared to younger adult patients
- **Type 2 Diabetes:** Wegovy® tablets have not been studied for weight reduction in adults with T2D and obesity or overweight. Administration of Wegovy® injection resulted in less weight reduction in patients with T2D and obesity or overweight compared to those without T2D and obesity or overweight

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

wegovy®
semaglutide tablets 25mg injection 1.7mg | 2.4mg | 7.2mg

Scan here to learn more about dosing Wegovy®

Trade Unit Specifications

Pills and bottles not to size.

Pill Information

	Wegovy® 1.5 mg trade unit	Wegovy® 4 mg trade unit	Wegovy® 9 mg trade unit	Wegovy® 25 mg trade unit
Product				
Generic	(semaglutide) tablets			
Package Presentation	30 x 1.5 mg per bottle	30 x 4 mg per bottle	30 x 9 mg per bottle	30 x 25 mg per bottle
NDC	0169-4415-31	0169-4404-31	0169-4409-31	0169-4425-31

Injection Information

Product	**Wegovy®**: Each pen delivers 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg **Wegovy® HD**: Each pen delivers 7.2 mg					
Generic	(semaglutide) injection					
Needles	4 needles included; no separate prescription or co-pay required					
Expiration Dating	24 months from the date of manufacture					
Package Presentation	 4 x 0.25 mg per box	 4 x 0.5 mg per box	 4 x 1 mg per box	 4 x 1.7 mg per box	 4 x 2.4 mg per box	 4 x 7.2 mg per box
NDC	0169-4525-14	0169-4505-14	0169-4501-14	0169-4517-14	0169-4524-14	0169-4572-14

Patients may receive a Wegovy® patient starter kit at their prescriber's office that contains a 1-month supply of 4 Wegovy® 0.25 mg dose pens. If so, their next prescription may be the 0.5 mg dose.

Medicare GLP-1 Bridge patients do **not** need a new prior authorization if switching between Wegovy® pen and pill.

Please see Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

References: 1. Medicare GLP-1 Bridge. Centers for Medicare & Medicaid Services. Updated April 6, 2026. Accessed May 29, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge **2.** Wegovy® [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.

novo nordisk®

wegovy® semaglutide tablets 25mg injection 1.7mg | 2.4mg | 7.2mg